Sacituzumab tirumotecan plus Iparomlimab
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer
Trial Timeline
Feb 1, 2026 → Jan 1, 2028
NCT ID
NCT07348861About Sacituzumab tirumotecan plus Iparomlimab
Sacituzumab tirumotecan plus Iparomlimab is a phase 2 stage product being developed by Sun Pharmaceutical for Cervical Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07348861. Target conditions include Cervical Cancer.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Cancer were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07348861 | Phase 2 | Recruiting |
Competing Products
20 competing products in Cervical Cancer